BTLA: An Emerging Target in Immunotherapy – New Insights into Cancer and Autoimmune Diseases
BTLA: An Emerging Target in Immunotherapy – New Insights into Cancer and Autoimmune Diseases1. The Emerging Role of BTLA in Immune Regulation The advent of immune checkpoint inhibitors (ICIs) marks a major breakthrough in cancer treatment, significantly improving outcomes for patients with vari...
Detailed information

Macrophage Migration Inhibitory Factor (MIF): A Pleiotropic Target Linking Inflammation and Cancer
Macrophage Migration Inhibitory Factor (MIF): A Pleiotropic Target Linking Inflammation and Cancer1. MIF Background: Structure, Expression Regulation, and Basic Biological Characteristics Macrophage migration inhibitory factor (MIF), initially named for its ability to inhibit macrophage migration, is...
Detailed information

Groundbreaking! "Cancer Immunol Res": mRNA-LNP Targeting FAP Reprograms T Cells In Vivo, Outperforming Traditional CAR-T in Pancreatic Cancer
Groundbreaking! "Cancer Immunol Res": mRNA-LNP Targeting FAP Reprograms T Cells In Vivo, Outperforming Traditional CAR-T in Pancreatic CancerThe difficulty in treating solid tumors lies largely in cancer-associated fibroblasts (CAFs) and the dense stroma they secrete, which act as key accomplices. They form a physical barrier that not only impedes drug penetr...
Detailed information

GPR20: From "Orphan" to a Promising Novel Target for Overcoming Drug-Resistant GIST
GPR20: From "Orphan" to a Promising Novel Target for Overcoming Drug-Resistant GISTIn the field of cancer therapy, overcoming drug resistance remains a significant challenge for researchers. GPR20, a long-silent "orphan" GPCR, is emerging into the spotlight due to its unique profile in drug-resistant g...
Detailed information

IL1RAP: Background, Research Mechanisms, Signaling Pathways, Related Diseases, and Latest Advances in Drug Development
IL1RAP: Background, Research Mechanisms, Signaling Pathways, Related Diseases, and Latest Advances in Drug Development1. Background and Significance of IL1RAP Research Interleukin-1 receptor accessory protein (IL1RAP) is a key co-receptor in the IL-1 family signaling pathways, extensively involved in immune and inflamma...
Detailed information

 Western Blotting: Principles, Step-by-Step Workflow, and Troubleshooting Guide
Western Blotting: Principles, Step-by-Step Workflow, and Troubleshooting GuideSince its development in 1979 by Towbin and colleagues, Western blotting (WB) has become an indispensable tool for detecting specific proteins in a complex sample [1]. Its enduring value lies in its ability to provide in...
Detailed information

Targeting EphA2: An Emerging Focus in Combating Tumor Drug Resistance and Metastasis
Targeting EphA2: An Emerging Focus in Combating Tumor Drug Resistance and MetastasisTumor drug resistance and metastasis are major causes of cancer treatment failure and patient mortality. Confronting this clinical challenge, scientists have turned their attention to a critical "signaling hub" on cancer...
Detailed information

In-depth Dialogue on the "Core Triangle" of Inflammation: How IL-6, IL-1β, and TNF-α Interact to Drive Disease Progression?
In-depth Dialogue on the "Core Triangle" of Inflammation: How IL-6, IL-1β, and TNF-α Interact to Drive Disease Progression?Inflammation is a key defense mechanism for maintaining homeostasis and responding to injury, but its dysregulation becomes a critical pathological basis for various chronic diseases. Interleukin-6 (IL-6), Interleukin-1β ...
Detailed information

Targeting TNFRSF13B: Dual-Target Strategies Usher in New Focus for Treating Tumors and Autoimmune Diseases
Targeting TNFRSF13B: Dual-Target Strategies Usher in New Focus for Treating Tumors and Autoimmune DiseasesTNFRSF13B (TACI), a molecule playing a central role in immune regulation, has become a new focal point for cross-domain breakthroughs in tackling tumors and autoimmune diseases due to its functional diversity. Current re...
Detailed information

SIGLEC15: An Emerging Immune Checkpoint Target in Tumor Immunotherapy
SIGLEC15: An Emerging Immune Checkpoint Target in Tumor ImmunotherapySIGLEC15 is an emerging immune checkpoint molecule widely expressed in various tumors, closely associated with immune evasion, treatment resistance, and poor prognosis. It plays a key role in tumor immunosuppression by i...
Detailed information

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1